8/22/2024

Hypromellose Ophthalmic Solution

Products Affected - Description

- Goniotaire, Altaire, 2.5%, 15 mL NDC 59390-0182-13

Reason for the Shortage

- Akorn ceased operations in February 2023.1
- Altaire has Goniotaire on shortage due to a voluntary recall.[2]
- Hub has Vista Gonio available.[3]

Available Products

- Vista Gonio, Hub Pharmaceuticals, 2.5%, 15 mL 1 count, NDC 77790-0022-15

Estimated Resupply Dates

- Altaire has Goniotaire 2.5% ophthalmic solution in 15 mL bottles on back order and the company cannot estimate a release date.[2]

Alternative Agents & Management

- Hypromellose-containing products are used in ocular examinations and to treat dry eye.[4] There are products available ranging from hypromellose 0.2% to 2.5%.[4] The American Academy of Ophthalmology does not recommend a specific product over another.[5] Use products without preservatives if applying more than 4 times daily.[5]

References

1. Akorn (personal communication). June 8, July 13, September 7, October 25, December 13 and 26, 2018; March 1, May 8, July 29, September 17, December 18, 2019; January 30, April 27, June 30, and September 9 and 30, 2020; January 12, April 7, May 14, June 30, July 21, August 26, October 7, December 22, 2021; March 30, June 16, August 26, November 21, 2022; and February 22, 2023.
2. Altaire Pharmaceuticals (personal communication). June 8, July 11, September 5, October 25, December 13, 2018; May 8 and 22, September 17, and December 18, 2019; September 10, 2020; January 12, April 5, July 1, August 26, December 22, 2021; March 31, June 16, August 26, November 21, 2022, January 12, April 26, July 14, September 18, 2023; March 22 and August 22, 2024.
3. Hub (personal communication). November 27, 2023; January 23, April 23, and August 16, 2024.
4. Lexi-Drugs Online. Hudson, OH: Lexi-Comp, Inc; 2018.
5. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Patern Guidelines. Dry Eye Syndrome. American Academy of Ophthalmology website. www.aao.org/ppp. 2013. Accessed June 11, 2018.

Updated

Updated August 22, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created June 8, 2018 by Anthony Trovato, PharmD, BCPS. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.